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Treatment with corticosteroids can control mild to moderate
emesis during chemotherapy (Cassileth et al., 1983) and adds
to the antiemetic effect of high-dose metoclopramide in
severe emesis (Bruera et al., 1983). Moreover, pregnancy
induced nausea is more common among women with low
than high cortisol excretion (Jarnfelt-Samsioe et al., 1986).
These findings warrant an investigation whether endogenous
cortisol secretion is associated with nausea induced by
chemotherapy.
The aim of the present study was to relate endogenous
cortisol secretion to individual differences in chemotherapy
induced nausea and vomiting. Urinary cortisol excretion
remain stable over time, particularly during resting condi-
tions (Forsman & Lundberg, 1982). Therefore, night time
urine was collected to assay cortisol excretion. Self-reports
were used to assess nausea and vomiting.
Table I summarises the clinical features of the 21 con-
secutive outpatients and three inpatients receiving chemo-
therapy at the Karolinska Hospital who participated. None
received high emetogenic cytostatics such as, for example,
cisplatinum, and 12 subjects received no antiemetic treat-
ment. Patients having received chemotherapy courses within
1 year were excluded, as were patients on strong opioid
analgesics. Four patients were ineligible for analysis: one
patient failed to complete urine sampling, and three failed to
report nausea and vomiting. The remaining 20 patients (17
women and three men) had an average age of 50.6 years
(standard error of the mean: s.e.m. = 3.47) with a range of
35-76. Twelve patients were treated for breast cancer, five of
these received adjuvant therapy after surgery for stage 2
disease and seven were treated for metastatic cancer (stage
2-4). The five patients with gastrointestinal cancer all had
metastatic disease. The primary sites were large bowel
(n = 3), pancreas (n = 1) and one patient had liver metastases
from an unknown primary tumour. Two patients had non
Hodgkin's lymphomas and one was treated for Hodgkin's
disease.
The urinary sample was collected from the time of voiding
before going to bed until the time of rising, the night before
the second chemotherapy course. Urine was collected in a
plastic container with sodiumdisulfit as antioxidant. Volume
and collection time were noted and the specimens were stored
at - 18°C until analysed for cortisol by radioimmunoassay
with a sensitivity of 3-5 nmol 1' (kits from New England
Nuclear Corporation). Cross reactivity for 11-deoxycortisol,
corticosterone and 11 -deoxycorticosterone was 15, 2 and
0.5% respectively. Excretion rate was expressed as pmol
min-'.
Nausea was rated by the patients on a 100 mm visual
analog scale (VAS) during and after the second chemo-
therapy course. A zero score is anchored at the left end with
Table I Cancer diagnosis, chemotherapy and antiemetic/sedative
agents, gender and age in groups of high and low night-time cortisol
excretion
Low cortisol High cortisol
excretion excretion
(number of (number of
patients) patients)
Cancer Breast 6 6
diagnosis Gastrointestinal 3 2
Lymphoma 1 2
Chemotherapy MTX + 5-FU + C 4 1
agents A + 5-FU + C 2 4
Mi + 5-FU 0 1
5-FU+F 3 2
D+V+C+E 1 1
Mu+O+N+Pr 0 1
Antiemetic/ Dix + Di 4 1
sedative agents Mp 0 1
Mc 0 1
Dix+Di+Mc 1 0
No antiemetics 5 7
Gender Female 8 9
Male 2 1
Age (mean in years) 45.2 56.1
Cytotoxic agents: MTX = Methotrexate; 5-FU = 5-fluorouracil;
D = Doxorubicin; Mi = Mitomycin, V = Vincristin; E = Etoposid;
P = Procarbazin; F = Folinate; C = Cyclophosphamid; Mu = Mustin;
N= Natulanar; Pr = Prednisolon. Antiemetic/sedative agents: Dix =
Dixyrazin, Di = Dinatrium betamethason; Mp = Methylprednisolon;
Mc = Metoclopramid.
no nausea at all' and a maximum score of 100 denotes
'worst possible nausea'. Vomiting episodes were counted.
Self-reports of nausea (VAS) and vomiting were given during
(one report) and after (two reports) infusion on the treatment
day. Patients also reported their nausea and vomiting every
6th hour for the 2 following days. The daily averages of these
values are reported. Vomiting was excluded from further
analyses because of its low occurrence.
The median used to form groups high and low in cortisol
excretion was 60.5 pmol min-'. The high and low excretion
group had an average (s.e.m.) of 107.3 (10.8) and 31.4 (5.7)
pmol min-' respectively.
Figure 1 shows that the group with high compared to low
night-time cortisol excretion experienced significantly less
nausea.
Nausea was higher in patients with relatively lower cortisol
levels during (t(18) = 2.55; P<.02) and after (t(18) = 3.01;
P<.01) the chemotherapy infusion as well as on the first
(t(18) = 2.47; <,.02) and second (t(18) = 2.77; <.01) day
after treatment. The group with low excretion rates was
younger (45.2; s.e.m. = 2.5) than the group with high excre-
tion (56.1; s.e.m. = 3.3) (t(18) = 2.66; <.02). Using a median
split defined by age, the average level (s.e.m.) of nausea
during the treatment day was 12.1 (5.4) in young patients
and 4.9 (2.8) in older ones (t(18) = 1.18; n.s.). Averaged over
post-treatment days 1 and 2 nausea was 22.1 (8.0) and 12.0
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Figure 1 Self-reports ofnausea on a visual analogue scale (VAS)
during and after chemotherapy treatment. Groups high and low
in night time cortisol excretion were defined by a median split.
Vertical bars denote the standard error of the mean. The differ-
ences are significant at each point of time (P , .05). -0-
Group with high night-time cortisol excretion before treatment.
-*- Group with low night-time cortisol excretion before treat-
ment.
(7.0) in young and old patients respectively (t(18) = 1; n.s.).
Sex, diagnosis or type of antiemetic or cancer treatment were
not different in the 'high' and 'low' cortisol excretion groups
(see Table I). No patient had elevated serum creatinine and
six patients had at least one pathological serum liver enzyme.
Liver and kidney functions were unrelated both to cortisol
excretion and nausea ratings.
Urinary cortisol excretion significantly predicted chemo-
therapy related nausea. Relatively higher excretion rates were
always associated with relatively lower levels of nausea. The
predictive power was not secondary to sex, diagnosis, treat-
ment, kidney or liver function. A positive and significant
correlation between age and cortisol excretion emerged.
Thus, it could be argued that our results do not reflect a
causal relation between cortisol excretion and nausea, but
that age is associated both with nausea and cortisol excre-
tion, and confounds the association. The mechanism whereby
age influences nausea remains, however, unknown (c.f.
Andrews et al., 1988) and, in the present study, the associa-
tion between cortisol excretion and nausea was stronger than
the association between age and nausea. Since younger indi-
viduals tend to have lower cortisol levels than older persons
(Arnetz et al., in press) we suggest that differences in endo-
genous cortisol secretion is a mechanism partly explaining the
age variations in nausea during chemotherapy.
There are several hypotheses explaining an antiemetic
effect of cortisol. First, cortisol may reduce cerebral oedema,
which is known to be an emetic stimulus (Davis et al., 1986).
Second, it may affect the permeability of the blood-brain
barrier and limit the influx of emetic agents to the brain
(Davies et al., 1986). Third, cortisol possibly affects 5-hydro-
xytryptamine (5-HT) turnover in the central nervous system
by shunting the metabolism of tryptophan away from 5-HT
pathways (Young, 1981). We propose that the anti-inflam-
matory properties of cortisol may act to prevent the release
of serotonin in the gut or prevent activation of 5-HT recep-
tors in the gastrointestinal system.
We have demonstrated that endogenous cortisol levels
predict acute and delayed nausea during chemotherapy. This
supports the study of mechanisms involved in the antiemetic
action of cortisol and its use to identify patients in need of
intense antiemetic treatment when given chemotherapy with
low emetic potential.
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